Pharma is the sector where great businesses hide behind acronyms — ANDA, 483, DMF, NLEM, gRevlimid. This guide unpacks all of it, from the value chain to the filings that move stock prices, the way an equity analyst actually learns it on the desk.
In FMCG, a company sells soap; you can model volumes and price. In pharma, a company's fate can turn on a single inspection report from a regulator sitting 12,000 km away. Here is what makes it different — and why that difficulty is your edge once you learn the language.
The doctor prescribes, the patient pays, the insurer or government often reimburses, and the pharmacist may substitute. Demand analysis means understanding prescription behaviour, not consumer preference.
Every plant, every product, every price can be touched by a regulator — CDSCO and NPPA at home, US FDA, EMA, MHRA and WHO abroad. One adverse inspection can shut a plant's exports overnight.
An API plant takes 3–4 years from ground-breaking to regulatory approval. A complex generic can take 5+ years and multiple litigation rounds before a single rupee of revenue. Quarterly numbers can mislead badly.
Revenue doesn't fade — it falls off cliffs. When a patent expires, generic competition can erode 80–90% of a drug's price within 18 months. Analysts model events, not just trends.
A single listed Indian pharma company may simultaneously run domestic branded generics, US generics, APIs, a CDMO arm and a biosimilar pipeline — each with different margins, risks and multiples. Sum-of-the-parts thinking is mandatory.
483s, OAI, Para-IV, FTF, DMF, gross margin vs EBITDA divergence, NLEM caps — the sector has its own dialect. This site exists to make that dialect fluent for you.
Every pharma business sits somewhere on this chain. Knowing where a company sits tells you its margin profile, its capital intensity and its regulatory exposure before you open a single annual report.
Identifying a molecule that treats a disease. Dominated by global innovators (Pfizer, Novartis, Eli Lilly). Indian role: growing via CROs and NCE research arms.
Key Starting Materials — the basic chemistry building blocks. Historically China-dominated; India's PLI scheme targets exactly this gap.
The Active Pharmaceutical Ingredient — the actual medicine molecule in powder form. India is a global API power (Divi's, Laurus, Aarti Drugs).
Converting API into the dosage form — tablet, capsule, injectable, inhaler, cream. This is where brands, bioequivalence and most listed-company value live.
CFA agents → stockists → chemists in India; wholesalers & pharmacy-benefit managers (PBMs) in the US. The US channel's consolidation is why generic prices erode.
An innovator (originator) drug is a newly discovered molecule protected by patents — priced high to recover ~US$1–2bn of R&D. A generic is a copy launched after patents expire, proving bioequivalence instead of repeating clinical trials — priced 80–90% lower. Indian pharma's global identity is being the world's most efficient generic machine, now climbing the ladder toward complex generics, biosimilars and novel research.
In India, generics carry brand names (Crocin, Augmentin, Telma) and are promoted to doctors by medical representatives — this is the "branded generics" model, with brand loyalty and pricing power. In the US and Europe, generics are unbranded commodities dispensed by chemical name, where the lowest bidder wins. Same molecule, utterly different economics.
Chronic therapies (diabetes, cardiac, CNS, respiratory) are taken for life — sticky prescriptions, steady growth, premium valuations. Acute therapies (antibiotics, pain, gastro) are episodic and seasonal. Analysts always check a company's chronic:acute mix — a rising chronic share usually deserves a higher multiple.
India stopped recognising product patents on medicines. Indian firms could legally re-engineer any global drug via a different chemical process. This single law created the Indian generic industry.
Created the modern US generic pathway (ANDA) and the Para-IV / 180-day exclusivity system — the legal machinery Indian exporters would later master.
India joined WTO in 1995 and restored product patents in 2005. Reverse-engineering the newest drugs for the domestic market ended; the industry pivoted to exports, complex generics and R&D.
The Drug Price Control Order shifted price caps to a market-based formula on all medicines in the National List of Essential Medicines (NLEM), administered by the NPPA.
A wave of warning letters and import alerts (Ranbaxy's consent decree being the landmark) forced an industry-wide remediation of data-integrity and quality culture — and taught analysts to track Form 483s religiously.
India supplied vaccines to 100+ countries, the government launched Production-Linked Incentive schemes for APIs/KSMs, and global supply chains began de-risking away from China — a structural tailwind for Indian CDMOs and API makers.
Semaglutide (Ozempic/Wegovy) goes off-patent in India in 2026 — the biggest generic opportunity in a decade, with a queue of Indian players ready with generic launches and peptide API capacity.
Indian pharma is not one business — it's a dozen. Each segment below has its own economics, its own risks, and its own set of listed champions. Tap any segment to open the full breakdown: what it is, why it matters, what to watch, and who the players are.
This is the Indian Pharmaceutical Market (IPM) — every medicine sold to an Indian patient. It is the emotional and financial home base of almost every listed Indian pharma company, and it behaves unlike any other generic market on earth.
The defining quirk: in India, generics carry brand names. When a patent expires elsewhere, the drug becomes a nameless commodity dispensed by chemical name. In India, ten companies sell the same molecule under ten different brands — Telma, Cardace, Amlong — and the doctor prescribes the brand, not the molecule. That single fact means a company can build a decades-long franchise, charge a premium, and defend it against cheaper rivals, because the prescription habit sits with the doctor, not the price tag. The whole domestic model is therefore a marketing and relationship business dressed as a pharma business: armies of medical representatives (MRs) visit doctors, and field-force productivity is a core metric.
Company → C&F (carrying & forwarding) agent → stockist/distributor → retail chemist → patient. Roughly 20% of the maximum retail price is trade margin. Because ~50%+ of Indian health spending is out-of-pocket (the patient pays cash, no insurer), affordability is political — which is exactly why price control exists.
Analysts obsess over the chronic vs. acute split. Chronic (cardiac, diabetes/anti-diabetic, CNS/neuro, respiratory) means a patient takes the drug for life — sticky, compounding, recession-proof revenue. Acute (anti-infectives, gastro, pain, vitamins) is episodic and seasonal. A rising chronic share almost always earns a company a higher valuation multiple.
A 70%+ domestic + chronic mix earns a premium P/E to an export-heavy peer, because the earnings are steadier and far less binary. Domestic = quality of earnings.
The US is the world's largest and most profitable drug market, and cracking it is how Indian pharma became a global force. But this is also the segment that has humbled the biggest names — where a single inspection or a wave of price erosion can wipe out a year of profit.
To sell a generic in the US you file an ANDA (Abbreviated New Drug Application) with the US FDA. "Abbreviated" because you skip the billion-dollar clinical trials of the original and instead prove bioequivalence — that your copy behaves identically in the body. Approval count and pipeline value are the currency of this business.
Plain oral generics (a tablet anyone can make) have become brutally competitive. The US buying side consolidated into three purchasing consortiums that control ~90% of generic volume — so they dictate price. The result is relentless price erosion: high-single to double-digit % every year on the base business. This is the silent margin killer, and management commentary on erosion "moderating" vs "accelerating" moves stocks.
Value has migrated to complex generics — products that are hard to make and hard to copy, so fewer players compete and prices hold: injectables, inhalers (respiratory), transdermal patches, ophthalmics, dermatology, and now peptides (the GLP-1 opportunity). This is where every serious Indian company is now investing.
If you challenge a patent (a Para-IV filing) and win as the First-to-File (FTF), you get 180 days of exclusivity — a window where you and the innovator are the only sellers, and margins are extraordinary. The textbook case is gRevlimid (generic Revlimid), which delivered windfall profits to several Indian firms. The catch: it's a one-off, and it invites litigation.
"gDrug" (little-g) = the generic version — gRevlimid = generic Revlimid. Always ask two questions: is this quarter flattered by a one-off, and what's the FDA status of the plant behind the revenue?
Every finished tablet starts as a white powder: the Active Pharmaceutical Ingredient (API), also called the bulk drug — the actual molecule that treats the disease. Everything else (fillers, coating, packaging) is just delivery. API makers are the chemists of the industry.
This is a process-chemistry and engineering business, not a marketing one. Competitive edge comes from yield, cost, purity, backward integration and environmental compliance — not brands. A company either uses its API captively (to feed its own formulations) or sells it to other formulators worldwide. The passport to sell is a DMF (Drug Master File) filed with a regulator, which certifies the API for use in that market (USDMF for the US, CEP for Europe).
Here's the uncomfortable truth: the "pharmacy of the world" depends on someone else's chemistry. India imports a very large share of its KSMs (Key Starting Materials) and intermediates — the basic building blocks — from China, which spent decades subsidising scale in fermentation and basic chemicals. When Chinese supply or prices move, Indian API margins swing. The government's PLI (Production-Linked Incentive) scheme for bulk drugs exists specifically to rebuild domestic KSM/fermentation capacity and cut this dependency.
China+1 — global buyers de-risking away from single-country (China) sourcing — is a multi-year tailwind for Indian API makers who can offer scale and quality.
API is a commodity-cyclical business at the bottom and a specialty business at the top. The re-rating happens when a bulk-drug maker climbs toward CDMO / patented-molecule work.
If US generics is a gold rush, CDMO is selling the picks and shovels. A Contract Development & Manufacturing Organisation makes molecules — often patented, high-value ones — for other companies, typically innovator Big Pharma that would rather outsource chemistry than build it. (CRAMS = Contract Research & Manufacturing Services, the older term.)
The beauty of the model: you are an arms dealer, not a soldier. You don't own a single drug's fate, you serve many customers, and once a global pharma company validates and audits your plant for a specific molecule, switching away is painful and slow — so revenue is sticky and relationships run for years. The higher up the value chain you go (patented molecules, late-stage / commercial supply), the better and more durable the margins.
The proposed US BIOSECURE Act would restrict US biopharma from working with certain Chinese CDMOs (notably WuXi). If it passes, billions of dollars of outsourced work could shift to trusted alternatives — and India is first in line. Combined with broad China+1 re-shoring, this is the clearest structural theme in the whole sector for the coming decade.
CDMO is the market's favourite structural story — but it's lumpy and back-ended. Value the order book and the customer roster, not one quarter's revenue.
Everything above is small-molecule chemistry — drugs built atom by atom in a reactor. Biologics are a different universe: large, complex molecules (antibodies, insulins, vaccines) grown inside living cells. They treat cancer, autoimmune disease and diabetes, they cost a fortune, and they are the fastest-growing, highest-value corner of medicine.
A biosimilar is the "generic" of a biologic — but because you can never copy a living-cell product exactly, regulators require its own clinical trials, not just a bioequivalence study. That makes biosimilars far harder and costlier to launch than a chemical generic — which is the whole point: high barriers mean few competitors and far less price erosion. The biggest patent cliffs of the next decade (Humira-class autoimmune drugs, oncology monoclonal antibodies) are all biologics.
Vaccines are a distinct, scale-and-cold-chain business. India makes roughly 60% of the world's vaccine doses by volume, and the Serum Institute of India is the single largest vaccine manufacturer on the planet — yet it is unlisted, so most retail investors have never owned a share of the world's biggest vaccine maker.
Biosimilars are a "jam tomorrow" story: enormous addressable market, but cash goes out for years first. Track the balance sheet and the approval calendar, not the TAM slide.
Not drug-makers, but the "healthcare" cousins that analysts cover on the same desk — and value with a completely different toolkit. If pharma is products, this is services.
Hospitals are essentially real-estate-plus-skilled-services businesses. The economics turn on how full the beds are and how much each bed earns. Watch ARPOB (Average Revenue Per Occupied Bed), occupancy %, the mix of mature vs. newly-added beds (new beds lose money before they ramp), and the specialty mix (oncology & cardiac pay far more than general medicine).
Diagnostics (pathology labs, imaging) is a high-margin, trust-and-network business: patients pick a lab brand they trust, and density of collection centres drives volume. It's now being disrupted by online aggregators and aggressive price competition, which has compressed the once-fat margins.
Different universe, different maths — don't use a drug-pipeline framework here. Per-bed and per-test economics, occupancy and network density are the whole game.
The corner of pharma that behaves like consumer goods. OTC (Over-The-Counter) products are bought without a prescription — analgesic balms, cough & cold, antacids, vitamins, wellness, sexual health. The buyer is the shopper, not the doctor, so this is brand-led, advertising-driven, and mercifully free of FDA/plant drama.
Because demand is created by brand and distribution rather than prescription, these businesses are valued more like a consumer-staples company (steady volumes, pricing power, high return on capital) than a drug-maker. The holy grail is an Rx-to-OTC switch: take a trusted prescription brand, get it de-scheduled, and sell it directly to households with FMCG-style repeat buying.
The dream is turning a doctor-driven brand into a household name — swapping prescription dependence for shelf presence, ad power and repeat purchase.
Pharma manufacturing clusters where three things line up: tax/subsidy incentives, ports & logistics, and a talent pool. That's why a handful of states dominate — and why an analyst should know which company's plants sit where, because location drives cost, incentives and even regulatory-inspection exposure.
Why an analyst maps the plants: location decides tax incentives, freight cost and which regulator inspects the site. It also concentrates risk — if most of a company's US revenue flows from one facility, a single FDA Import Alert on that plant is existential, not a blip. Always know which plant makes the money.
The single most confusing thing for newcomers is who controls what. India runs a two-track system: one authority controls quality & approvals, a completely separate one controls prices. Here's the chain of command.
Quality, safety & approval of drugs. Headed by the DCGI.
Fixes & caps prices of essential medicines under DPCO.
Approves new drugs, clinical trials & imports nationally.
Issue manufacturing & sale licences; inspect plants locally.
Rule of thumb: CDSCO decides if a drug is good enough to sell; NPPA decides how much you can charge for it. They report up different ministries and rarely overlap — which is exactly why a company can be squeezed on price (NPPA) even while sailing through quality (CDSCO), and vice-versa.
Pharma is run on paperwork, and some of that paper moves share prices by double digits in a day. These are the documents to know cold — what they are, and how worried you should be when one appears in the news.
| Form / Filing | What it is | Why it matters to a stock | Signal |
|---|---|---|---|
| ANDA | Abbreviated New Drug Application — the US FDA application to sell a generic in the US | Each approval = a new revenue stream. Pipeline of pending ANDAs = future growth. | Positive |
| DMF | Drug Master File — certifies an API/ingredient with a regulator | The "currency" of the API business; DMF count signals reach & capability. | Positive |
| NDA / 505(b)(2) | New Drug Application — full approval for a novel or modified drug | Higher-value, differentiated products; a step up the innovation ladder. | Positive |
| Para-IV / FTF | A patent challenge; First-to-File wins 180-day US exclusivity | Potential windfall profits (the classic gRevlimid story). Also litigation risk. | High-stakes |
| Form 483 | US FDA inspection observations issued at the end of a plant audit | The number and severity of observations signal quality problems. Markets react fast. | Caution |
| EIR | Establishment Inspection Report — the FDA's closing verdict on an inspection | A "VAI/NAI" clean EIR clears a plant; it's the all-clear analysts wait for. | Resolution |
| Warning Letter | Formal FDA escalation after unresolved 483 issues | Can freeze new approvals from that plant; a serious overhang on the stock. | Negative |
| Import Alert | FDA bans products from a specific plant entering the US | Directly cuts off US revenue from that site — often a sharp single-day fall. | Severe |
| OAI / VAI / NAI | Inspection classifications: Official Action / Voluntary Action / No Action Indicated | OAI = trouble (action needed); NAI = clean. The one-line verdict analysts scan for. | Varies |
| USDMF / CEP | US Drug Master File / EU Certificate of Suitability for an API | Regulatory approvals that open API sales in the US & EU respectively. | Positive |
The mental model: approval-type filings (ANDA, DMF, NDA) build the future; inspection-type filings (483, Warning Letter, Import Alert) threaten the present. A great pharma analyst tracks both calendars — the launch pipeline and the plant-audit cycle — for every company they follow.
You can't assess this industry without knowing the rulebook it lives inside. These are the laws, orders and codes that decide what a company can make, how it can price, how it must promote, and what happens when it slips up. Know these and most pharma headlines suddenly make sense.
The mother law. It governs the import, manufacture, distribution and sale of drugs & cosmetics, defines what a "drug" is, sets up the licensing regime, and empowers inspectors to seize sub-standard or spurious medicine. Every plant runs on licences issued under it.
The schedule under the 1940 Act that lays down manufacturing-quality standards — plant hygiene, equipment, documentation, testing. It was substantially tightened recently after cough-syrup export tragedies, forcing smaller units to upgrade or shut. A rising compliance bar that rewards quality leaders.
The Drug (Prices Control) Order empowers the NPPA to cap prices of essential medicines listed in the National List of Essential Medicines. Ceiling prices are set by a market-based formula; non-scheduled drugs can raise prices only ~10% a year. This is the single biggest domestic-margin lever the government holds.
India restored product patents in 2005 (TRIPS), but kept a famous safeguard: Section 3(d) bars "evergreening" — patenting trivial tweaks of known molecules. The landmark Novartis (Glivec) v. Union of India case upheld it. India also allows compulsory licensing in public-health emergencies.
The code governing how companies may promote drugs to doctors — restricting gifts, freebies, sponsored travel and inducements. Historically voluntary and weakly enforced, it's under pressure to become mandatory. Freebies-to-doctors is a live governance and tax issue (see the Apex Labs tax ruling).
Modernised the framework for approving new drugs and running clinical trials in India — timelines, ethics-committee oversight, compensation for trial injury, and provisions to fast-track drugs for unmet needs. It made India a more predictable place to run trials.
The Narcotic Drugs & Psychotropic Substances Act governs habit-forming and controlled drugs — opioids, certain sedatives, precursors. Companies handling these face strict licensing, quotas and record-keeping. Relevant for pain-management and certain API makers.
Dispensing requires a registered pharmacist and a valid licence; Schedule H/H1/X drugs need a prescription. Online pharmacies still operate in a regulatory grey area — draft e-pharmacy rules have been debated for years without final clarity, a real overhang for digital-health businesses.
The pattern to remember: India deliberately balances two goals that pull in opposite directions — rewarding innovation (patents) while guaranteeing affordable access (Section 3(d), compulsory licensing, DPCO price caps). Every big pharma-policy fight in India is some version of that tug-of-war. Spot which side a headline is on and you'll understand the stakes instantly.
Forget generic ratios for a moment. These are the pharma-specific metrics an analyst pulls first when a company reports — with the rough ranges to sanity-check against.
How rich the product mix is. Complex generics, branded domestic & biosimilars lift it; plain orals & APIs pull it down. A widening gap between gross margin and EBITDA margin flags heavy R&D or field-force spend.
The headline profitability number. Premium names run 28%+; API/commodity players sit lower. Always ask what a one-off (FTF windfall, forex) is doing to it.
Investment in the future pipeline. Too low = thin future; too high without launches = value destruction. Watch how much is expensed vs. capitalised.
The silent margin killer in US generics. Management commentary on erosion "moderating" or "accelerating" moves stocks.
Is the company beating the Indian Pharmaceutical Market growth rate? Consistent outperformance = franchise strength.
The stock of future US launches. Analysts value the pipeline, not just today's revenue — especially the count of complex filings.
Chronic therapy share signals earnings durability. A rising chronic mix usually earns a valuation re-rating.
Biosimilars & big US M&A can load the balance sheet. Leverage plus a plant under a Warning Letter is the danger combination.
Return on capital employed — the ultimate test of whether all that plant & R&D capex is actually earning its keep.
The difference between a good pharma analyst and a great one is often knowing what to be suspicious of. These are the recurring red flags.
Quality issues can be fixed; data-integrity issues (falsified or deleted records) signal a culture problem and take years and reputation to remediate.
A single FTF/Para-IV windfall can inflate a year's profit. Always look at the ex-one-off base business before paying up on the P/E.
Stretching credit to book sales into a tough US channel is a classic quality-of-earnings warning.
Capitalising R&D instead of expensing it props up near-term profit while hiding the true cost of the pipeline.
If one facility drives most US revenue, a single Import Alert is an existential risk, not a blip.
Governance basics that apply everywhere — but pharma's complex multi-entity structures make them especially worth scrutinising.
A mix of the well-known and the genuinely surprising. Every card is a question first — guess, then flip it.
Tap to flip →
3rd by volume, ~14th by value. India makes an enormous share of the world's pills but earns far less per pill — the signature of a generic-volume powerhouse still climbing toward higher-value products.
Tap to flip →
It supplies roughly 20% of global generic medicine by volume and about 40% of US generics. When Americans fill a generic prescription, there's a good chance it was made in India.
Tap to flip →
Serum Institute of India — the world's largest vaccine maker by doses, yet it's unlisted, so most retail investors have never held it.
Tap to flip →
GLP-1s (semaglutide — Ozempic/Wegovy). The obesity/diabetes blockbuster goes off-patent in India in 2026, triggering a race among Indian firms for generic launches and peptide-API capacity.
Tap to flip →
Around 50%+ of health spend is out-of-pocket — patients pay cash directly. That makes affordability and price control (NPPA) politically charged in a way the US, with its insurers, isn't.
Tap to flip →
China — India imports a large share of KSMs & intermediates from China. The "pharmacy of the world" quietly depends on someone else's chemistry, which is exactly what PLI aims to fix.
The structural stories an analyst is tracking heading into the mid-2020s. Directional, not dated — always confirm specifics against current filings and news before acting.
With semaglutide's India patent lapsing in 2026, domestic majors are lining up generic launches and building peptide-API capacity. It's the most talked-about pipeline event in years and a potential domestic-growth accelerant.
The proposed US BIOSECURE Act and broad "China+1" de-risking are steering innovator manufacturing toward Indian CDMOs — the clearest multi-year structural theme in the sector.
India tightened its GMP standard (Schedule M) and stepped up plant scrutiny after cough-syrup export incidents. Smaller units face upgrade costs; compliant leaders gain share and credibility.
Production-Linked Incentive schemes aim to rebuild domestic fermentation & KSM capacity and cut the China dependency that sits underneath the whole industry.
After years of brutal US price erosion, the base is steadier and value has shifted decisively to injectables, inhalation and peptides — where Indian firms are investing hardest.
Indian players are chasing biosimilars of high-value biologics (oncology, autoimmune). High barriers mean fewer competitors and more durable economics than plain generics — if the capital and approvals line up.
Where the sector is heading, and the questions that will decide which companies win the next decade.
The whole industry is moving from plain generics → complex generics → biosimilars → novel research. Each rung means fewer competitors, harder science and fatter, more durable margins. The next decade's winners will be the companies that climb, not the ones defending the crowded, price-eroding bottom rung.
China+1 de-risking, Western re-shoring and the proposed US BIOSECURE Act could make India the default alternative for API & CDMO work. If quality and scale keep pace, this is a genuine multi-year, structural tailwind — the single most-discussed theme on the desk.
Rising incomes, an ageing population, deepening insurance penetration (Ayushman Bharat), and a lifestyle-disease epidemic all expand the home market. It's the steadiest, least-binary growth engine in the sector — and it compounds quietly every year.
Semaglutide (Ozempic/Wegovy) goes off-patent in India in 2026 — the biggest generic opportunity in a decade. A queue of Indian firms is ready with launches and peptide-API capacity, potentially reshaping domestic growth and the injectable-CDMO map at once.
Indian firms are filing more novel molecules, 505(b)(2) products and their own NCEs. New-drug discovery is still nascent and cash-hungry, but the direction of travel has clearly changed — from copying molecules to creating them.
AI-led molecule discovery, continuous/digital manufacturing, and e-pharmacy distribution are bending cost curves and go-to-market. Watch who adopts fastest — early movers in AI discovery and digitised plants will separate from the pack.
API/chemistry plants are pollution-heavy, and global buyers increasingly audit environmental & labour standards. Cleaner processes, water recycling and solvent recovery are shifting from cost centre to competitive advantage — and a licence to keep exporting.
Oncology, rare diseases, cell & gene therapy and personalised medicine are where global value is concentrating. Indian players are beginning to build specialty franchises and branded pipelines in the US & emerging markets — the high-margin future.
Four persistent risks temper the optimism: US FDA dependence (one inspection can hurt), domestic price control, China raw-material reliance, and rising ESG/environmental scrutiny. A great analyst prices the upside and respects these tail risks.
The 2030 thesis in one line: India is trying to graduate from the world's cheapest maker of medicines to a genuine innovator and trusted supply-chain partner — riding China+1, the GLP-1 wave and a domestic boom, while quality, R&D depth and clean chemistry decide who actually makes the leap.
Primary sources beat summaries. These are the places to verify a fact, track a filing, or go a layer deeper than any single guide can take you.
India's drug approvals, notifications, Schedule M & regulatory circulars.
Price-control orders, ceiling prices and NLEM updates straight from the source.
Inspection data, Warning Letters, Import Alerts and the Orange Book of approved drugs.
Look up any drug's approval status, applicant and history — the analyst's fact-check tool.
Policy, PLI scheme details and the government's strategic direction for the sector.
Clean, free industry overviews, sizing and export data — a solid starting orientation.
Free financials, ratios & concall transcripts to practise the KPIs on this page on real companies.
India's Pharmaceutical Export Promotion Council — export statistics, market reports & policy notes.
The list that decides who can supply UN/tender markets — a quality & access benchmark for exporters.